Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Emugrobart - Chugai Pharmaceutical

Next Previous
Drug Profile

Emugrobart - Chugai Pharmaceutical

Alternative Names: Emubrobart; Emubrobart - Roche; GYM-329; RG-6237; RG-70240​; RO-7204239

Latest Information Update: 03 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Roche
  • Class Antibodies; Monoclonal antibodies; Obesity therapies
  • Mechanism of Action Myostatin inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Spinal muscular atrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Spinal muscular atrophy
  • Phase II Facioscapulohumeral muscular dystrophy; Obesity
  • No development reported Neuromuscular disorders

Most Recent Events

  • 14 Aug 2025 Hoffmann-La Roche plans to initiate a phase I trial for Type 2 Diabetes Mellitus and Obesity (Treatment experienced) (SC) (NCT07137585)
  • 31 Jul 2025 Chugai Pharmaceuticals plans to file regulatory application for Obesity in the year 2028 or beyond (Chugai Pharmaceuticals pipeline, July 2025)
  • 05 May 2025 Phase-II clinical trials in Obesity in USA (SC) (NCT06965413)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top